Reporting owner · CIK 0002030840

Heltzen Michael

SEC Form 4 history across 1 companies, 6 transactions and 1 filings.

CEOChief Executive OfficerEXOZYMES INC.
Open-market transaction mix100% buys5 buys · 0 sales

Available history · Aug 19, 2026 – Aug 26, 2026

Filings1Form 4 records
Buying$6.4K5 purchases
Selling$00 sales
Net value$6.4KBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from available history.
Heltzen Michael transactions · 20 per page
CompanyInsiderActivityDisclosed valueFiled (ET)
EXOZEXOZYMES INC.
Heltzen MichaelCEOA · grantSEC filing ↗$56.5kView disclosure →
EXOZEXOZYMES INC.
Heltzen MichaelCEOP · buySEC filing ↗$750View disclosure →
EXOZEXOZYMES INC.
Heltzen MichaelCEOP · buySEC filing ↗$1.88kView disclosure →
EXOZEXOZYMES INC.
Heltzen MichaelCEOP · buySEC filing ↗$1.90kView disclosure →
EXOZEXOZYMES INC.
Heltzen MichaelCEOP · buySEC filing ↗$1.84kView disclosure →
EXOZEXOZYMES INC.
Heltzen MichaelCEOP · buySEC filing ↗$30View disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

buy at EXOZYMES INC. on Aug 26, 2026 valued at $1,900.

Review SEC filing
Latest sale

No open-market insider sale is available.

Monthly open-market activity

Last 1 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Aug 202650$6,405.17$0.00$6,405.17

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$1.3K
Median P/S size$1.8K
Direct6
Indirect0
Aug 26, 2026buy

Filing-only signals

Deterministic matches in this insider's history

No filing-only signal badges matched this history.

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

6 observations · Aug 19, 2026 – Aug 26, 2026. Window ends at the latest available report, not today.

Selected observation · Aug 26, 202614,453 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Aug 19, 202613,853Sep 2, 2026View transaction
Aug 25, 202614,203Sep 2, 2026View transaction
Aug 25, 202613,953Sep 2, 2026View transaction
Aug 26, 202614,708Sep 2, 2026View transaction
Aug 26, 202614,704Sep 2, 2026View transaction
Aug 26, 202614,453Sep 2, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Heltzen Michael Insider Activity FAQ

SEC Form 4 context

Who is Heltzen Michael?

Heltzen Michael is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002030840.

Which companies has Heltzen Michael reported transactions for?

EXOZYMES INC., Invizyne Technologies Inc

When was Heltzen Michael's latest insider buy?

buy at EXOZYMES INC. on Aug 26, 2026 valued at $1,900.

When was Heltzen Michael's latest insider sale?

No open-market insider sale is available for this period.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.